Cargando…
The dark side of mRNA translation and the translation machinery in glioblastoma
Among the different types of cancer affecting the central nervous system (CNS), glioblastoma (GB) is classified by the World Health Organization (WHO) as the most common and aggressive CNS cancer in adults. GB incidence is more frequent among persons aged 45–55 years old. GB treatments are based on...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042294/ https://www.ncbi.nlm.nih.gov/pubmed/36994107 http://dx.doi.org/10.3389/fcell.2023.1086964 |
_version_ | 1784912901590482944 |
---|---|
author | Montiel-Dávalos, Angélica Ayala, Yeniffer Hernández, Greco |
author_facet | Montiel-Dávalos, Angélica Ayala, Yeniffer Hernández, Greco |
author_sort | Montiel-Dávalos, Angélica |
collection | PubMed |
description | Among the different types of cancer affecting the central nervous system (CNS), glioblastoma (GB) is classified by the World Health Organization (WHO) as the most common and aggressive CNS cancer in adults. GB incidence is more frequent among persons aged 45–55 years old. GB treatments are based on tumor resection, radiation, and chemotherapies. The current development of novel molecular biomarkers (MB) has led to a more accurate prediction of GB progression. Moreover, clinical, epidemiological, and experimental studies have established genetic variants consistently associated with the risk of suffering GB. However, despite the advances in these fields, the survival expectancy of GB patients is still shorter than 2 years. Thus, fundamental processes inducing tumor onset and progression remain to be elucidated. In recent years, mRNA translation has been in the spotlight, as its dysregulation is emerging as a key cause of GB. In particular, the initiation phase of translation is most involved in this process. Among the crucial events, the machinery performing this phase undergoes a reconfiguration under the hypoxic conditions in the tumor microenvironment. In addition, ribosomal proteins (RPs) have been reported to play translation-independent roles in GB development. This review focuses on the research elucidating the tight relationship between translation initiation, the translation machinery, and GB. We also summarize the state-of-the-art drugs targeting the translation machinery to improve patients’ survival. Overall, the recent advances in this field are shedding new light on the dark side of translation in GB. |
format | Online Article Text |
id | pubmed-10042294 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100422942023-03-28 The dark side of mRNA translation and the translation machinery in glioblastoma Montiel-Dávalos, Angélica Ayala, Yeniffer Hernández, Greco Front Cell Dev Biol Cell and Developmental Biology Among the different types of cancer affecting the central nervous system (CNS), glioblastoma (GB) is classified by the World Health Organization (WHO) as the most common and aggressive CNS cancer in adults. GB incidence is more frequent among persons aged 45–55 years old. GB treatments are based on tumor resection, radiation, and chemotherapies. The current development of novel molecular biomarkers (MB) has led to a more accurate prediction of GB progression. Moreover, clinical, epidemiological, and experimental studies have established genetic variants consistently associated with the risk of suffering GB. However, despite the advances in these fields, the survival expectancy of GB patients is still shorter than 2 years. Thus, fundamental processes inducing tumor onset and progression remain to be elucidated. In recent years, mRNA translation has been in the spotlight, as its dysregulation is emerging as a key cause of GB. In particular, the initiation phase of translation is most involved in this process. Among the crucial events, the machinery performing this phase undergoes a reconfiguration under the hypoxic conditions in the tumor microenvironment. In addition, ribosomal proteins (RPs) have been reported to play translation-independent roles in GB development. This review focuses on the research elucidating the tight relationship between translation initiation, the translation machinery, and GB. We also summarize the state-of-the-art drugs targeting the translation machinery to improve patients’ survival. Overall, the recent advances in this field are shedding new light on the dark side of translation in GB. Frontiers Media S.A. 2023-03-13 /pmc/articles/PMC10042294/ /pubmed/36994107 http://dx.doi.org/10.3389/fcell.2023.1086964 Text en Copyright © 2023 Montiel-Dávalos, Ayala and Hernández. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Montiel-Dávalos, Angélica Ayala, Yeniffer Hernández, Greco The dark side of mRNA translation and the translation machinery in glioblastoma |
title | The dark side of mRNA translation and the translation machinery in glioblastoma |
title_full | The dark side of mRNA translation and the translation machinery in glioblastoma |
title_fullStr | The dark side of mRNA translation and the translation machinery in glioblastoma |
title_full_unstemmed | The dark side of mRNA translation and the translation machinery in glioblastoma |
title_short | The dark side of mRNA translation and the translation machinery in glioblastoma |
title_sort | dark side of mrna translation and the translation machinery in glioblastoma |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042294/ https://www.ncbi.nlm.nih.gov/pubmed/36994107 http://dx.doi.org/10.3389/fcell.2023.1086964 |
work_keys_str_mv | AT montieldavalosangelica thedarksideofmrnatranslationandthetranslationmachineryinglioblastoma AT ayalayeniffer thedarksideofmrnatranslationandthetranslationmachineryinglioblastoma AT hernandezgreco thedarksideofmrnatranslationandthetranslationmachineryinglioblastoma AT montieldavalosangelica darksideofmrnatranslationandthetranslationmachineryinglioblastoma AT ayalayeniffer darksideofmrnatranslationandthetranslationmachineryinglioblastoma AT hernandezgreco darksideofmrnatranslationandthetranslationmachineryinglioblastoma |